Younus Qamar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Younus Qamar has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Avinaash Maharaj
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University , London EC1M 6BQ
4 shared publications - Li F. Chan
Centre for Endocrinology, William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
4 shared publications - Louise A. Metherell
Centre of Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
2 shared publications - Rathi Prasad
Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
2 shared publications - Adrian J. L. Clark
Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, UK
1 shared publication - Angela Huebner
University Centre for Rare Diseases and Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
1 shared publication
Latest Publications
- 17 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 85
The lack of genotype: phenotype correlations in rare causes of primary adrenal insufficiency highlights the need for genetic testing
Background: Primary adrenal insufficiency (PAI) can be associated with significant morbidity in children of all ages, the most common cause being Congenital Adrenal Hyperplasia (CAH). Several other rare inherited causes of PAI have been identified over the years which lack diagnostic phenotypic or biochemical signs, leaving genetic testing as the only approach to make a definitive diagnosis. Our cohort involves >440 patients who presented with features of PAI – hypoglycaemia, hyperpigmentation and hypocortisolaemia without diagnostic characteristics of CAH. Targeted and whole exome sequencing has been conducted in 377 patients to date. Aim: Genotype:phenotype characterisation for our cohort’s five most common genes causing PAI. Results: We identified the genetic cause in 322/377 patients, the most common being mutations in MC2R (n=68/322), MRAP (n=53/322), NNT (n=44/322), STAR (n=28/322) and CYP11A1 (n=23/322). The relative risk of early age of onset of symptoms with an MRAP mutation as compared to other gene mutations causing PAI within our cohort was 1.5158 (95%CI: 0.9988-2.3003, PPP<0.0001) amongst our cohort. For CYP11A1 2/4 (50%) adrenals were described as small whereas for all others only 11/102 (11%) were abnormal. No other significant association with height or levels of other steroids were found between the genotypic and phenotypic characteristics of PAI. Discussion: A limitation of this study was the small sample size for each gene defect owing to the rarity of the disease. Our results suggest MRAP mutations present the earliest with lowest cortisol, while CYP11A1 have higher cortisol and smaller adrenal size however, with overlapping ranges this cannot be used for diagnosis. For CYP11A1 the higher cortisol levels may be due to over-representation of partial loss-of-function rs6161 variant in our population. These findings also highlight the importance of genetic testing since few clear genotype:phenotype correlations are obvious at diagnosis. Gaining a genetic diagnosis allows for the monitoring of patients for the pathological sequelae which can develop with different forms of PAI.
- 17 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 85
The lack of genotype: phenotype correlations in rare causes of primary adrenal insufficiency highlights the need for genetic testing
Background: Primary adrenal insufficiency (PAI) can be associated with significant morbidity in children of all ages, the most common cause being Congenital Adrenal Hyperplasia (CAH). Several other rare inherited causes of PAI have been identified over the years which lack diagnostic phenotypic or biochemical signs, leaving genetic testing as the only approach to make a definitive diagnosis. Our cohort involves >440 patients who presented with features of PAI – hypoglycaemia, hyperpigmentation and hypocortisolaemia without diagnostic characteristics of CAH. Targeted and whole exome sequencing has been conducted in 377 patients to date. Aim: Genotype:phenotype characterisation for our cohort’s five most common genes causing PAI. Results: We identified the genetic cause in 322/377 patients, the most common being mutations in MC2R (n=68/322), MRAP (n=53/322), NNT (n=44/322), STAR (n=28/322) and CYP11A1 (n=23/322). The relative risk of early age of onset of symptoms with an MRAP mutation as compared to other gene mutations causing PAI within our cohort was 1.5158 (95%CI: 0.9988-2.3003, PPP<0.0001) amongst our cohort. For CYP11A1 2/4 (50%) adrenals were described as small whereas for all others only 11/102 (11%) were abnormal. No other significant association with height or levels of other steroids were found between the genotypic and phenotypic characteristics of PAI. Discussion: A limitation of this study was the small sample size for each gene defect owing to the rarity of the disease. Our results suggest MRAP mutations present the earliest with lowest cortisol, while CYP11A1 have higher cortisol and smaller adrenal size however, with overlapping ranges this cannot be used for diagnosis. For CYP11A1 the higher cortisol levels may be due to over-representation of partial loss-of-function rs6161 variant in our population. These findings also highlight the importance of genetic testing since few clear genotype:phenotype correlations are obvious at diagnosis. Gaining a genetic diagnosis allows for the monitoring of patients for the pathological sequelae which can develop with different forms of PAI.
- 18 October 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 77
In vitro splicing assay proves the pathogenicity of intronic variants in MRAP
Familial glucocorticoid deficiency (FGD) is characterised by isolated glucocorticoid deficiency with retention of normal mineralocorticoid production. FGD causing mutations in the MC2R accessory protein, MRAP, often occur at the canonical donor splice-site of intron 3, presumed to result in skipping of the first coding exon with unknown consequences at the protein level. DNA from three patients (0 - 6 months) with high ACTH and/or low cortisol levels underwent whole exome sequencing. The proband in family 1 (P1) presented at 13 months and had a hyperpigmented sibling who died in neonatal period due to adrenal failure. Patient 2 (P2) had a family history of adrenal insufficiency and was hyperpigmented at birth and patient 3 (P3) had diffuse hyperpigmentation in the early neonatal period and low cortisol on formal testing at 16m. Variants were confirmed using Sanger sequencing and predicted splice-site mutations were investigated using an in vitrosplicing assay. Homozygous mutations in MRAP were identified in all three cases. Previously described, c.106+1delG (P1) and c.106+2dupT (P2) at the canonical donor splice-site of intron 3, were identified, with the former predicted to destroy the splice site and the latter to weaken it. These mutations in vitroresulted in the complete skipping of exon 3 with unknown consequence to the protein (p.?). A novel homozygous mutation in intron 4, c.206+5G>T was identified in P3 but was not predicted to alter splicing. However, in vitro, this mutation negates the canonical donor splice site and creates two different alternative sites, both resulting in frameshifts and predicted early termination of the protein (p.Val44fs*50, p.Asn70fs*92). Splice prediction protocols, though largely effective for variants within 2bp of exon/intron boundaries may not predict the true outcome of more distant base change(s), highlighting the necessity of functional assays to assign pathogenicity to them.
- 18 October 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 77
In vitro splicing assay proves the pathogenicity of intronic variants in MRAP
Familial glucocorticoid deficiency (FGD) is characterised by isolated glucocorticoid deficiency with retention of normal mineralocorticoid production. FGD causing mutations in the MC2R accessory protein, MRAP, often occur at the canonical donor splice-site of intron 3, presumed to result in skipping of the first coding exon with unknown consequences at the protein level. DNA from three patients (0 - 6 months) with high ACTH and/or low cortisol levels underwent whole exome sequencing. The proband in family 1 (P1) presented at 13 months and had a hyperpigmented sibling who died in neonatal period due to adrenal failure. Patient 2 (P2) had a family history of adrenal insufficiency and was hyperpigmented at birth and patient 3 (P3) had diffuse hyperpigmentation in the early neonatal period and low cortisol on formal testing at 16m. Variants were confirmed using Sanger sequencing and predicted splice-site mutations were investigated using an in vitrosplicing assay. Homozygous mutations in MRAP were identified in all three cases. Previously described, c.106+1delG (P1) and c.106+2dupT (P2) at the canonical donor splice-site of intron 3, were identified, with the former predicted to destroy the splice site and the latter to weaken it. These mutations in vitroresulted in the complete skipping of exon 3 with unknown consequence to the protein (p.?). A novel homozygous mutation in intron 4, c.206+5G>T was identified in P3 but was not predicted to alter splicing. However, in vitro, this mutation negates the canonical donor splice site and creates two different alternative sites, both resulting in frameshifts and predicted early termination of the protein (p.Val44fs*50, p.Asn70fs*92). Splice prediction protocols, though largely effective for variants within 2bp of exon/intron boundaries may not predict the true outcome of more distant base change(s), highlighting the necessity of functional assays to assign pathogenicity to them.
- Open Access
- 11 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8) , bvab086
Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years’ Experience in the UK
Context Although primary adrenal insufficiency (PAI) in children and young people is often due to congenital adrenal hyperplasia (CAH) or autoimmunity, other genetic causes occur. The relative prevalence of these conditions is poorly understood. Objective We investigated genetic causes of PAI in children and young people over a 25 year period. Design, Setting and Participants Unpublished and published data were reviewed for 155 young people in the United Kingdom who underwent genetic analysis for PAI of unknown etiology in three major research centers between 1993 and 2018. We pre-excluded those with CAH, autoimmune, or metabolic causes. We obtained additional data from NR0B1 (DAX-1) clinical testing centers. Intervention and Outcome Measurements Genetic analysis involved a candidate gene approach (1993 onward) or next generation sequencing (NGS; targeted panels, exomes) (2013-2018). Results A genetic diagnosis was reached in 103/155 (66.5%) individuals. In 5 children the adrenal insufficiency resolved and no genetic cause was found. Pathogenic variants occurred in 11 genes: MC2R (adrenocorticotropin receptor; 30/155, 19.4%), NR0B1 (DAX-1; 7.7%), CYP11A1 (7.7%), AAAS (7.1%), NNT (6.5%), MRAP (4.5%), TXNRD2 (4.5%), STAR (3.9%), SAMD9 (3.2%), CDKN1C (1.3%), and NR5A1/steroidogenic factor-1 (SF-1; 0.6%). Additionally, 51 boys had NR0B1 variants identified through clinical testing. Although age at presentation, treatment, ancestral background, and birthweight can provide diagnostic clues, genetic testing was often needed to define the cause. Conclusions PAI in children and young people often has a genetic basis. Establishing the specific etiology can influence management of this lifelong condition. NGS approaches improve the diagnostic yield when many potential candidate genes are involved.
- 11 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8) , bvab086
Open AccessGenetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years’ Experience in the UK
Context Although primary adrenal insufficiency (PAI) in children and young people is often due to congenital adrenal hyperplasia (CAH) or autoimmunity, other genetic causes occur. The relative prevalence of these conditions is poorly understood. Objective We investigated genetic causes of PAI in children and young people over a 25 year period. Design, Setting and Participants Unpublished and published data were reviewed for 155 young people in the United Kingdom who underwent genetic analysis for PAI of unknown etiology in three major research centers between 1993 and 2018. We pre-excluded those with CAH, autoimmune, or metabolic causes. We obtained additional data from NR0B1 (DAX-1) clinical testing centers. Intervention and Outcome Measurements Genetic analysis involved a candidate gene approach (1993 onward) or next generation sequencing (NGS; targeted panels, exomes) (2013-2018). Results A genetic diagnosis was reached in 103/155 (66.5%) individuals. In 5 children the adrenal insufficiency resolved and no genetic cause was found. Pathogenic variants occurred in 11 genes: MC2R (adrenocorticotropin receptor; 30/155, 19.4%), NR0B1 (DAX-1; 7.7%), CYP11A1 (7.7%), AAAS (7.1%), NNT (6.5%), MRAP (4.5%), TXNRD2 (4.5%), STAR (3.9%), SAMD9 (3.2%), CDKN1C (1.3%), and NR5A1/steroidogenic factor-1 (SF-1; 0.6%). Additionally, 51 boys had NR0B1 variants identified through clinical testing. Although age at presentation, treatment, ancestral background, and birthweight can provide diagnostic clues, genetic testing was often needed to define the cause. Conclusions PAI in children and young people often has a genetic basis. Establishing the specific etiology can influence management of this lifelong condition. NGS approaches improve the diagnostic yield when many potential candidate genes are involved.
- 6 November 2019
- Published by Bioscientifica in Endocrine Abstracts
Splice-site mutations in the melanocortin-2 receptor accessory protein that lead to early-onset familial glucocorticoid deficiency type 2
Background: Familial glucocorticoid deficiency (FGD) is characterised by isolated glucocorticoid deficiency, with preserved mineralocorticoid production. FGD type 2 is caused by mutations in MRAP encoding the melanocortin-2 receptor accessory protein. MRAP has a single transmembrane domain essential to its function in trafficking the MC2R/ACTH receptor. 15 mutations in MRAP have been described, five of which are within the canonical donor splice-site of intron 3 and predicted to cause complete exon skipping. Patients and methods: Proband 1 (family 1) was diagnosed at 13 months. His sibling was hyperpigmented but was neither formally diagnosed nor treated and died neonatally after a febrile illness. Proband 2 (family 2), diagnosed at birth, was hyperpigmented with elevated ACTH levels. Both patients have responded to hydrocortisone replacement therapy. The coding exons of MC2R and MRAP were Sanger sequenced from patient DNA. The effect of splice-site mutations was assessed in silico by Human Splicing Finder (HSF3.0) and in vitro by a splicing assay, comparing wild type and mutant heterologous minigenes. Results: Homozygous mutations, c.106+1delG (family 1) and c.106+2dupT (family 2) were identified in the donor splice-site of intron 3 of MRAP. HSF3.0 predicted c.106+1delG destroys the splice site and c.106+2dupT weakens it. However, there is another high-scoring donor site 23 bp downstream which, if utilised, would result in the addition of frame-shifting 22 bp for c.106+1delG BUT the possibility of in-frame insertion of 24 bp for the c.106+2dupT mutation. An in vitro splicing assay utilised to assess this demonstrated that both variants resulted in complete skipping of exon 3. Conclusion: Both splice-site mutations lead to complete skipping of exon 3 of MRAP, containing the translational start site, the next methionine from which translation could start is after the essential transmembrane domain. Hence, this is likely to result in the absence of any functional protein which is in keeping with the severe, early presentation in these two families.
- 6 November 2019
- Published by Bioscientifica in Endocrine Abstracts
Splice-site mutations in the melanocortin-2 receptor accessory protein that lead to early-onset familial glucocorticoid deficiency type 2
Background: Familial glucocorticoid deficiency (FGD) is characterised by isolated glucocorticoid deficiency, with preserved mineralocorticoid production. FGD type 2 is caused by mutations in MRAP encoding the melanocortin-2 receptor accessory protein. MRAP has a single transmembrane domain essential to its function in trafficking the MC2R/ACTH receptor. 15 mutations in MRAP have been described, five of which are within the canonical donor splice-site of intron 3 and predicted to cause complete exon skipping. Patients and methods: Proband 1 (family 1) was diagnosed at 13 months. His sibling was hyperpigmented but was neither formally diagnosed nor treated and died neonatally after a febrile illness. Proband 2 (family 2), diagnosed at birth, was hyperpigmented with elevated ACTH levels. Both patients have responded to hydrocortisone replacement therapy. The coding exons of MC2R and MRAP were Sanger sequenced from patient DNA. The effect of splice-site mutations was assessed in silico by Human Splicing Finder (HSF3.0) and in vitro by a splicing assay, comparing wild type and mutant heterologous minigenes. Results: Homozygous mutations, c.106+1delG (family 1) and c.106+2dupT (family 2) were identified in the donor splice-site of intron 3 of MRAP. HSF3.0 predicted c.106+1delG destroys the splice site and c.106+2dupT weakens it. However, there is another high-scoring donor site 23 bp downstream which, if utilised, would result in the addition of frame-shifting 22 bp for c.106+1delG BUT the possibility of in-frame insertion of 24 bp for the c.106+2dupT mutation. An in vitro splicing assay utilised to assess this demonstrated that both variants resulted in complete skipping of exon 3. Conclusion: Both splice-site mutations lead to complete skipping of exon 3 of MRAP, containing the translational start site, the next methionine from which translation could start is after the essential transmembrane domain. Hence, this is likely to result in the absence of any functional protein which is in keeping with the severe, early presentation in these two families.